Maitreyee Bhattacharyya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maitreyee Bhattacharyya has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Siddhesh Arun Kalantri
Institute of Hematology and Transfusion Medicine, Medical College and Hospital Kolkata, Kolkata, West Bengal, India
8 shared publications Rudra Ray
Institute of Hematology and Transfusion Medicine (IHTM) MCH Kolkata India
7 shared publicationsMalay Kumar Ghosh
A Department of Haematology , Nilratan Sarkar Medical College & Hospital , Kolkata , West Bengal , India
6 shared publications- Manoranjan Mahapatra
Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India
6 shared publications Jyoti Shaw
Department of Molecular Biology, #Institute of Hematology and Transfusion Medicine, Medical College Hospital Kolkata, West Bengal, India
5 shared publicationsRenu Saxena
5 shared publications
Latest Publications
- 7 July 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-2
Response to the Letter to Editor related to the article "Indian College of Hematology (ICH) and Indian Council of Medical Research (ICMR) Joint Consensus Document on Management and Control of Sickle Cell Disease in India" 2026
- 7 July 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-2
Response to the Letter to Editor related to the article "Indian College of Hematology (ICH) and Indian Council of Medical Research (ICMR) Joint Consensus Document on Management and Control of Sickle Cell Disease in India" 2026
- 1 April 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 679-696
Best Practices for Thalassaemia Management: Recommendations by Indian Society of Haematology and Blood Transfusion
Thalassemia comprises a heterogeneous group of most common monogenetic disorder and inherited autosomal recessive hemoglobin disorders characterized by defective globin chain synthesis, resulting in hemolysis, ineffective erythropoiesis, chronic anemia, and multisystem complications. India bears a substantial thalassemia burden, with millions of carriers and over 12,000 affected births annually, necessitating standardized, context-appropriate management strategies. These recommendations by the Indian Society of Haematology and Blood Transfusion (ISHBT) provide comprehensive, evidence-informed guidance for the diagnosis, treatment, monitoring, and prevention of thalassemia across diverse healthcare settings in India. The recommendation developed through a structured, multidisciplinary consensus process and expert review, these guidelines aim to harmonize best practices nationwide while allowing flexibility for regional adaptation. Their implementation is expected to improve survival, quality of life, and long-term outcomes for individuals living with thalassemia in India. The guidelines address the clinical spectrum, including transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT), emphasizing early diagnosis through hematological indices, hemoglobin fraction analysis, and molecular testing when indicated. Clear recommendations are provided for rational blood transfusion practices, iron overload monitoring, and timely initiation of iron chelation therapy to prevent cardiac, hepatic, endocrine, and skeletal complications. Disease-specific management of iron-related organ damage, infections, endocrine dysfunction, fertility issues, pregnancy, and emergency scenarios is outlined. Curative and disease-modifying options including hematopoietic stem cell transplantation, gene therapy, and newer agents such as luspatercept, hydroxyurea, and thalidomide are outlined. Preventive strategies, highlighting carrier screening, antenatal and prenatal diagnosis, genetic counseling, and public awareness initiatives.
- 1 April 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 679-696
Best Practices for Thalassaemia Management: Recommendations by Indian Society of Haematology and Blood Transfusion
Thalassemia comprises a heterogeneous group of most common monogenetic disorder and inherited autosomal recessive hemoglobin disorders characterized by defective globin chain synthesis, resulting in hemolysis, ineffective erythropoiesis, chronic anemia, and multisystem complications. India bears a substantial thalassemia burden, with millions of carriers and over 12,000 affected births annually, necessitating standardized, context-appropriate management strategies. These recommendations by the Indian Society of Haematology and Blood Transfusion (ISHBT) provide comprehensive, evidence-informed guidance for the diagnosis, treatment, monitoring, and prevention of thalassemia across diverse healthcare settings in India. The recommendation developed through a structured, multidisciplinary consensus process and expert review, these guidelines aim to harmonize best practices nationwide while allowing flexibility for regional adaptation. Their implementation is expected to improve survival, quality of life, and long-term outcomes for individuals living with thalassemia in India. The guidelines address the clinical spectrum, including transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT), emphasizing early diagnosis through hematological indices, hemoglobin fraction analysis, and molecular testing when indicated. Clear recommendations are provided for rational blood transfusion practices, iron overload monitoring, and timely initiation of iron chelation therapy to prevent cardiac, hepatic, endocrine, and skeletal complications. Disease-specific management of iron-related organ damage, infections, endocrine dysfunction, fertility issues, pregnancy, and emergency scenarios is outlined. Curative and disease-modifying options including hematopoietic stem cell transplantation, gene therapy, and newer agents such as luspatercept, hydroxyurea, and thalidomide are outlined. Preventive strategies, highlighting carrier screening, antenatal and prenatal diagnosis, genetic counseling, and public awareness initiatives.
- Open Access
- 31 January 2026
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 162 (6) , 905-907
New thalassemia mutations from West Bengal
- 31 January 2026
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 162 (6) , 905-907
Open AccessNew thalassemia mutations from West Bengal
- 23 January 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (2) , 302-343
Indian College of Hematology (ICH)& Indian Council of Medical Research (ICMR) Joint Consensus Document on Management and Control of Sickle Cell Disease in India
The magnitude of the problem of sickle cell disease (SCD) in India is very large and diverse. For people living with SCD there are several unmet health care needs making it pertinent to focus on recognizing the important public health burden of SCD in the country. In a bid to achieve this goal, the Indian College of Hematology (ICH) of the Indian Society of Hematology and Blood Transfusion (ISHBT) in collaboration with Indian Council of Medical Research (ICMR) has formulated a Guideline on Management and Control of Sickle Cell Disease in India. This was achieved by a national taskforce comprising top experts from the field who held multiple sessions to deliberate on different aspects and form consensus on preparing a comprehensive document on SCD care in India. The taskforce has presented its recommendations on various aspects of SCD in India, all of which have been evaluated based on the best evidence. Where the evidence was weak, the recommendations have been based on consensus among the experts. This review which is adapted from the comprehensive guideline document gives a concise treatise on various aspects of sickle cell disease in India along with specific recommendations. The section on screening and diagnosis provides an evidence-based background to scientifically select the most appropriate and feasible test option(s) in various Indian practice settings. The other aspects covered in this review are management of SCD in stable condition, iron overload and chelation therapy, vaso-occlusive crisis, management of other complications of SCD, blood transfusion in SCD, haematopoietic stem cell transplant and gene therapy in SCD, immunization and antibiotic prophylaxis in SCD and monitoring of patients with SCD. It also gives guidance on special circumstances such as pregnancy and surgery in SCD. It concludes with a note on prevention and control of SCD in India with an outline of a defined roadmap to make this possible.
- 23 January 2026
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (2) , 302-343
Indian College of Hematology (ICH)& Indian Council of Medical Research (ICMR) Joint Consensus Document on Management and Control of Sickle Cell Disease in India
The magnitude of the problem of sickle cell disease (SCD) in India is very large and diverse. For people living with SCD there are several unmet health care needs making it pertinent to focus on recognizing the important public health burden of SCD in the country. In a bid to achieve this goal, the Indian College of Hematology (ICH) of the Indian Society of Hematology and Blood Transfusion (ISHBT) in collaboration with Indian Council of Medical Research (ICMR) has formulated a Guideline on Management and Control of Sickle Cell Disease in India. This was achieved by a national taskforce comprising top experts from the field who held multiple sessions to deliberate on different aspects and form consensus on preparing a comprehensive document on SCD care in India. The taskforce has presented its recommendations on various aspects of SCD in India, all of which have been evaluated based on the best evidence. Where the evidence was weak, the recommendations have been based on consensus among the experts. This review which is adapted from the comprehensive guideline document gives a concise treatise on various aspects of sickle cell disease in India along with specific recommendations. The section on screening and diagnosis provides an evidence-based background to scientifically select the most appropriate and feasible test option(s) in various Indian practice settings. The other aspects covered in this review are management of SCD in stable condition, iron overload and chelation therapy, vaso-occlusive crisis, management of other complications of SCD, blood transfusion in SCD, haematopoietic stem cell transplant and gene therapy in SCD, immunization and antibiotic prophylaxis in SCD and monitoring of patients with SCD. It also gives guidance on special circumstances such as pregnancy and surgery in SCD. It concludes with a note on prevention and control of SCD in India with an outline of a defined roadmap to make this possible.
- Open Access
- 21 August 2025
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 26 (1) , 1-6
β-thalassemia due to de novo mutation IVS1-5(G > C) at HBB gene in three cases from West Bengal
Background: Beta-thalassemia is the commonest single-gene blood disorder worldwide with global prevalence rate of 5–7%. It is also a major health problem in India as its prevalence varies from 4 to 17% across different states in the country. Beta-thalassemia is highly prevalent in eastern and north-eastern India. In West Bengal, the most common HBB mutation is CD26(G > A) and IVS1-5(G > C). These mutations cause thalassemia major syndrome when present in heterozygous condition affecting both the alleles, and disease is commonly known as HbE-beta-thalassemia. However, IVS1-5(G > C) is β0 severe mutation and leads to thalassemia major syndrome in homozygous state as well. Here, we report three cases of de novo IVS1-5(G > C) mutation where father is carrier but mother is normal. Cases presentation Three patients having different presentations were referred for genetic testing. One patient was behaving as thalassemia intermedia but HPLC reports similar to that of thalassemia trait. Family screening shows that father is β-thalassemia carrier but mother was normal. However, genetic analysis revealed that the patient was homozygous for IVS1-5(G > C) mutation. Another patient with high HbF and abnormal RBC indices also carried IVS1-5(G > C) mutation in homozygous state. Third case is of a 12-year-old female with severe anemia, received more than 100 blood transfusion. Her spleen was removed and having IVS1-5(G > C) mutation in homozygous condition. In all the three cases, father was the thalassemia carrier having IVS1-5(G > C) mutation in heterozygous state but mother was harboring normal alleles of HBB gene. Conclusion: Inheritance testing was performed by VNTR D1S80 analysis. VNTR test confirmed the paternity and maternity of the three probands. Hence, it is highly probable that de novo DNA mutation occurred during embryogenesis of fetus development. Such reports indicate that globin genes are one of the hotspots for DNA alterations in human genome and predispose the risk of disease in newborn even in healthy couples.
- 21 August 2025
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 26 (1) , 1-6
Open Accessβ-thalassemia due to de novo mutation IVS1-5(G > C) at HBB gene in three cases from West Bengal
Background: Beta-thalassemia is the commonest single-gene blood disorder worldwide with global prevalence rate of 5–7%. It is also a major health problem in India as its prevalence varies from 4 to 17% across different states in the country. Beta-thalassemia is highly prevalent in eastern and north-eastern India. In West Bengal, the most common HBB mutation is CD26(G > A) and IVS1-5(G > C). These mutations cause thalassemia major syndrome when present in heterozygous condition affecting both the alleles, and disease is commonly known as HbE-beta-thalassemia. However, IVS1-5(G > C) is β0 severe mutation and leads to thalassemia major syndrome in homozygous state as well. Here, we report three cases of de novo IVS1-5(G > C) mutation where father is carrier but mother is normal. Cases presentation Three patients having different presentations were referred for genetic testing. One patient was behaving as thalassemia intermedia but HPLC reports similar to that of thalassemia trait. Family screening shows that father is β-thalassemia carrier but mother was normal. However, genetic analysis revealed that the patient was homozygous for IVS1-5(G > C) mutation. Another patient with high HbF and abnormal RBC indices also carried IVS1-5(G > C) mutation in homozygous state. Third case is of a 12-year-old female with severe anemia, received more than 100 blood transfusion. Her spleen was removed and having IVS1-5(G > C) mutation in homozygous condition. In all the three cases, father was the thalassemia carrier having IVS1-5(G > C) mutation in heterozygous state but mother was harboring normal alleles of HBB gene. Conclusion: Inheritance testing was performed by VNTR D1S80 analysis. VNTR test confirmed the paternity and maternity of the three probands. Hence, it is highly probable that de novo DNA mutation occurred during embryogenesis of fetus development. Such reports indicate that globin genes are one of the hotspots for DNA alterations in human genome and predispose the risk of disease in newborn even in healthy couples.
- 20 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (1) , 161-165
Anemia in Pregnancy - Is it all Iron Deficiency?
Anemia in pregnancy is defined as Hb < 11 g/ dl. It is a huge burden causing death in around 80%. There is scanty literature available on prevalence of anaemia among pregnancy along with its determinants from Eastern India. The objective of our study was to assess the prevalence and aetiology of anaemia among pregnant mothers in urban population of eastern India. This is an observational, cross-sectional study conducted amongst the antenatal mothers visiting Lady Dufferin Hospital, Kolkata, West Bengal, India from - June 2010 to December 2021, for a duration of eleven years six months. Complete haemogram was performed after collecting 2cc EDTA blood sample. Other tests done include HPLC, serum ferritin, vitamin B 12, folate. 42349 antenatal mothers were enrolled in the study. 44.16% (18703/42349) of this study population had anaemia. Out of which, 1.5% had severe anaemia, 35.46% moderate and 63.02% had mild anaemia. The age range of the study population was 15 years 3 months to 46 years 1 month, with a mean age of 30 years 7 months. Of the entire cohort 9.5% ( 4023 / 42349 ) were detected to be thalassaemia carriers. Serum Ferritin level was less than 30ug/dl in 52.3% ( 9781/ 18703 ) of anaemic mothers. This study though documented a lower prevalence in urban mothers, the prevalence was higher compared to the global standards. The prevalence of anemia among teenage mothers was higher (59.78%) and anemia was more in primigravida (63.02% ), which indicates higher prevalence among the adolescents and young women. Anemia in most of the mother was mild ( 63.02% ), however some national as well as international studies reported moderate anemia as the most prevalent one. A significant percentage of pregnant women are anemic, which is significant in teenage pregnancies and primigravida. More importance to anemia control programs and mass awareness is needed to reduce the significant burden of anaemia.
- 20 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (1) , 161-165
Anemia in Pregnancy - Is it all Iron Deficiency?
Anemia in pregnancy is defined as Hb < 11 g/ dl. It is a huge burden causing death in around 80%. There is scanty literature available on prevalence of anaemia among pregnancy along with its determinants from Eastern India. The objective of our study was to assess the prevalence and aetiology of anaemia among pregnant mothers in urban population of eastern India. This is an observational, cross-sectional study conducted amongst the antenatal mothers visiting Lady Dufferin Hospital, Kolkata, West Bengal, India from - June 2010 to December 2021, for a duration of eleven years six months. Complete haemogram was performed after collecting 2cc EDTA blood sample. Other tests done include HPLC, serum ferritin, vitamin B 12, folate. 42349 antenatal mothers were enrolled in the study. 44.16% (18703/42349) of this study population had anaemia. Out of which, 1.5% had severe anaemia, 35.46% moderate and 63.02% had mild anaemia. The age range of the study population was 15 years 3 months to 46 years 1 month, with a mean age of 30 years 7 months. Of the entire cohort 9.5% ( 4023 / 42349 ) were detected to be thalassaemia carriers. Serum Ferritin level was less than 30ug/dl in 52.3% ( 9781/ 18703 ) of anaemic mothers. This study though documented a lower prevalence in urban mothers, the prevalence was higher compared to the global standards. The prevalence of anemia among teenage mothers was higher (59.78%) and anemia was more in primigravida (63.02% ), which indicates higher prevalence among the adolescents and young women. Anemia in most of the mother was mild ( 63.02% ), however some national as well as international studies reported moderate anemia as the most prevalent one. A significant percentage of pregnant women are anemic, which is significant in teenage pregnancies and primigravida. More importance to anemia control programs and mass awareness is needed to reduce the significant burden of anaemia.
- Open Access
- 22 October 2024
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 160 (2) , 210-216
Infrared thermography: An investigative tool for detection of subclinical bleed in hemophilia on prophylaxis
Background & objectives: Subclinical joint bleed is a matter of concern in individuals with hemophilia on prophylaxis. Ultrasonography (USG) is mostly used for the screening of subclinical bleeds in such individuals but it has its own limitations. Thus a more comprehensive technology is required for the detection of the same. This study undertook to evaluate the efficacy of infrared thermography (IRT) for detection of subclinical joint bleeds and its comparison with ultrasonography and MRI (Magnetic Resonance Imaging), considering MRI as the gold standard. Methods: Forty eight asymptomatic individuals with hemophiliacs on prophylaxis and 15 healthy males as controls were recruited. IRT, USG and MRI were done in all participants included in the study. FLIR camera systems were used for the capture of thermograms of the joints in both the study groups. Results: The mean of maximum temperature difference>0.5K (ΔT max >0.5K) as compared to a healthy joint was considered as significant. Subclinical bleeds were detected in 23.9, 7.29 and 27.08 per cent participants by IRT, USG and MRI respectively. Sensitivity and specificity of IRT and USG was detected to be 88.4 and 97.67 per cent, and 26.9 and 99 per cent, respectively. Interpretation & conclusions: The findings of this study suggest that IRT is an effective tool for detection of subclinical joint bleeds in individuals with hemophilia and can be used for the monitoring of the joints in such individuals.
- 22 October 2024
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 160 (2) , 210-216
Open AccessInfrared thermography: An investigative tool for detection of subclinical bleed in hemophilia on prophylaxis
Background & objectives: Subclinical joint bleed is a matter of concern in individuals with hemophilia on prophylaxis. Ultrasonography (USG) is mostly used for the screening of subclinical bleeds in such individuals but it has its own limitations. Thus a more comprehensive technology is required for the detection of the same. This study undertook to evaluate the efficacy of infrared thermography (IRT) for detection of subclinical joint bleeds and its comparison with ultrasonography and MRI (Magnetic Resonance Imaging), considering MRI as the gold standard. Methods: Forty eight asymptomatic individuals with hemophiliacs on prophylaxis and 15 healthy males as controls were recruited. IRT, USG and MRI were done in all participants included in the study. FLIR camera systems were used for the capture of thermograms of the joints in both the study groups. Results: The mean of maximum temperature difference>0.5K (ΔT max >0.5K) as compared to a healthy joint was considered as significant. Subclinical bleeds were detected in 23.9, 7.29 and 27.08 per cent participants by IRT, USG and MRI respectively. Sensitivity and specificity of IRT and USG was detected to be 88.4 and 97.67 per cent, and 26.9 and 99 per cent, respectively. Interpretation & conclusions: The findings of this study suggest that IRT is an effective tool for detection of subclinical joint bleeds in individuals with hemophilia and can be used for the monitoring of the joints in such individuals.
- Open Access
Alpha globin gene alterations modifying the phenotype of homozygous beta thalassaemia
The phenotype of β‐thalassemia varies widely. The primary determinant is the type of beta‐globin gene mutation; however, there are secondary and tertiary modifiers also as associated alpha mutations, polymorphisms, as well as coinheritance of mutations affecting other related systems. Co‐inheritance of alpha thalassemia mutations is known to ameliorate the severity of HbE‐β thalassemia. However, the role of alpha globin gene alterations (deletions and triplication) is not well illustrated in homozygous β‐thalassemia. Here we evaluated the role of alpha globin gene alterations in 122 β‐thalassemia patients having IVS1‐5 (G > C) homozygous mutation. β‐thalassemia mutations were detected by ARMS PCR and alpha mutations by GAP‐PCR. Gene expression by qRT‐PCR. Out of 122 cases, 15 patients had alpha 3.7 triplications (ααα3.7anti), 24 had alpha 3.7 kb deletion (−α3.7) mutation and three patients had 4.2 kb deletion (−α4.2). Patients were divided into two groups, requiring less than 8 units (NTDT) and more than 8 units (TDT) of blood transfusion per year (≥8U BT/year). The percentage of alpha deletion was significantly (p = 0.0042) high in NTDT (42.1%) as compared with TDT (13.2%). Conversely, the proportion of alpha triplication is high in the TDT as compared with NTDT. Even mean serum ferritin level was found to be significantly high in patients having alpha triplication as compared with those having alpha deletions (p = 0.0184) and normal alpha gene (p = 0.0003). α/β globin ratio was highest in TDT patients with alpha triplication and lowest in NTDT patients with alpha‐del. The results show that concurrent inheritance of alpha gene alterations influences the phenotypic severity of homozygous β‐thalassemia.
Open AccessAlpha globin gene alterations modifying the phenotype of homozygous beta thalassaemia
The phenotype of β‐thalassemia varies widely. The primary determinant is the type of beta‐globin gene mutation; however, there are secondary and tertiary modifiers also as associated alpha mutations, polymorphisms, as well as coinheritance of mutations affecting other related systems. Co‐inheritance of alpha thalassemia mutations is known to ameliorate the severity of HbE‐β thalassemia. However, the role of alpha globin gene alterations (deletions and triplication) is not well illustrated in homozygous β‐thalassemia. Here we evaluated the role of alpha globin gene alterations in 122 β‐thalassemia patients having IVS1‐5 (G > C) homozygous mutation. β‐thalassemia mutations were detected by ARMS PCR and alpha mutations by GAP‐PCR. Gene expression by qRT‐PCR. Out of 122 cases, 15 patients had alpha 3.7 triplications (ααα3.7anti), 24 had alpha 3.7 kb deletion (−α3.7) mutation and three patients had 4.2 kb deletion (−α4.2). Patients were divided into two groups, requiring less than 8 units (NTDT) and more than 8 units (TDT) of blood transfusion per year (≥8U BT/year). The percentage of alpha deletion was significantly (p = 0.0042) high in NTDT (42.1%) as compared with TDT (13.2%). Conversely, the proportion of alpha triplication is high in the TDT as compared with NTDT. Even mean serum ferritin level was found to be significantly high in patients having alpha triplication as compared with those having alpha deletions (p = 0.0184) and normal alpha gene (p = 0.0003). α/β globin ratio was highest in TDT patients with alpha triplication and lowest in NTDT patients with alpha‐del. The results show that concurrent inheritance of alpha gene alterations influences the phenotypic severity of homozygous β‐thalassemia.
- 3 May 2024
- Published by Taylor & Francis in Hemoglobin
- Vol. 48 (3) , 161-168
Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life
Transfusion-dependent thalassemia (TDT) is a major public health concern in India, requiring regular transfusions for survival. There is also significant morbidity caused by iron overload and transfusion related infections. Novel therapies targeting fetal hemoglobin induction are the need of the hour in resource-poor institutions for patients where transplant is not feasible for various reasons. This single arm, non-randomised prospective trial evaluated the efficacy and safety of a combination of low dose thalidomide and hydroxyurea in TDT along with the impact on quality of life (QoL). It included 41 TDT patients, who failed a reasonable trial of hydroxyurea. Complete response (CR) was defined as transfusion independence and partial response (PR) denoted at least a 50% reduction in transfusion requirement. The rest were defined as non-responders (NR). The mean age of the cohort was 20.78 years (range 12-45 years). There were 13 males and 28 females. Nineteen (46.3%), 7 (17.1%), and 15 (36.6%) patients achieved CR, PR, and no response respectively. The overall response rate (CR + PR) was 63.4%. There was a significant increase in hemoglobin levels with decrement in transfusion burden and ferritin levels. There were no significant adverse reactions. No significant predictors of response were found including amongst genetic modifiers. It improved the health related QoL amongst responders. The combination of thalidomide and hydroxyurea appear safe and effective in the reduction in transfusion requirement of TDT patients. The judicious use of these drugs can improve the quality of life and pave the way for patients not eligible for a stem cell transplant.
- 3 May 2024
- Published by Taylor & Francis in Hemoglobin
- Vol. 48 (3) , 161-168
Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life
Transfusion-dependent thalassemia (TDT) is a major public health concern in India, requiring regular transfusions for survival. There is also significant morbidity caused by iron overload and transfusion related infections. Novel therapies targeting fetal hemoglobin induction are the need of the hour in resource-poor institutions for patients where transplant is not feasible for various reasons. This single arm, non-randomised prospective trial evaluated the efficacy and safety of a combination of low dose thalidomide and hydroxyurea in TDT along with the impact on quality of life (QoL). It included 41 TDT patients, who failed a reasonable trial of hydroxyurea. Complete response (CR) was defined as transfusion independence and partial response (PR) denoted at least a 50% reduction in transfusion requirement. The rest were defined as non-responders (NR). The mean age of the cohort was 20.78 years (range 12-45 years). There were 13 males and 28 females. Nineteen (46.3%), 7 (17.1%), and 15 (36.6%) patients achieved CR, PR, and no response respectively. The overall response rate (CR + PR) was 63.4%. There was a significant increase in hemoglobin levels with decrement in transfusion burden and ferritin levels. There were no significant adverse reactions. No significant predictors of response were found including amongst genetic modifiers. It improved the health related QoL amongst responders. The combination of thalidomide and hydroxyurea appear safe and effective in the reduction in transfusion requirement of TDT patients. The judicious use of these drugs can improve the quality of life and pave the way for patients not eligible for a stem cell transplant.
- 25 April 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (3) , 538-539
Successful Stem Cell Transplantation from Varicella Infected Donor
- 25 April 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (3) , 538-539
Successful Stem Cell Transplantation from Varicella Infected Donor